- Price
- $76.60
- Day
- -0.48%
- Mkt Cap
- $9.72B
- 52W Range
- $11.16 – $79.94
- Volume
- 2.88M
- Beta
- 2.08
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
HB Wealth Management LLC purchased a new stake in 10x Genomics (NASDAQ: TXG) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 7,444 shares of the company's stock, valued at approximately $285,000. Other institutional investors have also recently modified their holdings of the company.
Read full article
10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.
Read full article
On September 08, 2026, 10x Genomics Inc (TXG) shares rose 4.7% today, bringing the current price to $65.61. The stock has seen significant volatility over the p
Read full article
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
Read full article
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
Read full article
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
Read full article